Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  ShangPharma Corp (ADR)    SHP

SummaryQuotesNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector news 

ShangPharma Corp (ADR) : ShangPharma Corporation Files 2011 Annual Report on Form 20-F

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/01/2012 | 11:05am CET

SHANGHAI, May 1, 2012 /PRNewswire-Asia-FirstCall/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that it has filed its annual report on Form 20-F for the year ended December 31, 2011 with the United States Securities and Exchange Commission (the "SEC"). The annual report can be accessed on ShangPharma's website at http://ir.shangpharma.com under the Investor Relations section. ShangPharma will provide a hard copy of its annual report on Form 20-F containing complete audited financial statements free of charge to its shareholders and ADS holders upon request. Requests should be directed to Ms. Lan Xie, VP of Finance and Investor Relations, by email at ir@shangpharma.com.

ABOUT SHANGPHARMA CORPORATION

ShangPharma Corporation (NYSE: SHP) is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com.

For further information, please contact:

ShangPharma
Ms. Lan Xie
VP of Finance and Investor Relations
Email: ir@shangpharma.com

Brunswick Group
Mr. Josh Gartner
Email: shangpharma@brunswickgroup.com
Phone: 86-10-5960-8600

SOURCE ShangPharma Corporation

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SHANGPHARMA CORP (ADR)
2014 AbbVie board ditches planned $55 billion Shire acquisition
2013 SHANGPHARMA CORP (ADR) : Rosen Law Firm Announces Investigation of ShangPharma C..
2012 SHANGPHARMA CORP (ADR) : ShangPharma Announces Third Quarter 2012 Results
2012 SHANGPHARMA CORP (ADR) : ShangPharma to Report Third Quarter 2012 Financial Resu..
2012 SHANGPHARMA CORP (ADR) : ShangPharma and Harbour Antibodies Announce Licensing A..
2012 SHANGPHARMA CORP (ADR) : ShangPharma Announces Second Quarter 2012 Results
2012 SHANGPHARMA CORP (ADR) : ShangPharma to Report Second Quarter 2012 Financial Res..
2012 SHANGPHARMA CORP (ADR) : ShangPharma Independent Committee Appoints Financial Ad..
2012 SHANGPHARMA CORP (ADR) : ShangPharma Independent Committee Appoints Chairman and..
2012DJU.S. HOT STOCK FUTURES : Hot stocks to watch
More news
Sector news : Biotechnology & Medical Research - NEC
12:36a Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
11/26 Johnson & Johnson approaches Actelion about takeover deal
More sector news : Biotechnology & Medical Research - NEC